



## **Gamida Cell to Present at the BTIG Virtual Biotechnology Conference**

August 3, 2021

BOSTON--(BUSINESS WIRE)--Aug. 3, 2021-- Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET.

The live webcast will be available on BTIG's conference website at the time of the event, after which it will be available through BTIG's research access.

In the fourth quarter of 2021, Gamida Cell is targeting a BLA submission for omidubicel, the first potential approval of a cell therapy for blood cancer patients in need of an allogeneic bone marrow transplant. In the second half of 2021, the Company is planning an IND submission to support the initiation of a Phase 1/2 clinical study of cryopreserved, off-the-shelf GDA-201 in patients with follicular and diffuse large b-cell lymphomas.

### **About Gamida Cell**

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit [www.gamida-cell.com](http://www.gamida-cell.com) or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTX.

### **Cautionary Note Regarding Forward Looking Statements**

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to anticipated regulatory submissions, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Gamida Cell's clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell's Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 9, 2021, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at <http://www.sec.gov>), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell's actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Gamida Cell as of the date of this release.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210803005052/en/): <https://www.businesswire.com/news/home/20210803005052/en/>

#### *For investors:*

Stephanie Ascher  
Stern Investor Relations, Inc.  
[stephanie.ascher@sternir.com](mailto:stephanie.ascher@sternir.com)  
1-212-362-1200

#### *For media:*

Rhiannon Jeselonis  
Ten Bridge Communications  
[rhiannon@tenbridgecommunications.com](mailto:rhiannon@tenbridgecommunications.com)  
1-978-417-1946

Source: Gamida Cell Ltd.